Tag: RNAi

In a significant leap forward in the ongoing battle against drug-resistant cancers, Gradalis, a forefront player in personalized cancer immunotherapy, has unveiled promising results for its innovative candidate, GRAD1405 bi-shRNAi. This groundbreaking therapeutic has exhibited a positive impact on three key KRAS mutations prevalent in drug-resistant lung, colon, and pancreatic cancers. The emergence of such…